Free Trial
NYSE:EBS

Emergent Biosolutions (EBS) Stock Price, News & Analysis

Emergent Biosolutions logo
$6.99 -0.12 (-1.69%)
Closing price 03:30 PM Eastern
Extended Trading
$6.98 0.00 (-0.07%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Emergent Biosolutions Stock (NYSE:EBS)

Key Stats

Today's Range
$6.88
$7.29
50-Day Range
$4.74
$7.08
52-Week Range
$4.02
$15.10
Volume
917,382 shs
Average Volume
1.73 million shs
Market Capitalization
$379.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33
Consensus Rating
Buy

Company Overview

Emergent Biosolutions Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

EBS MarketRank™: 

Emergent Biosolutions scored higher than 80% of companies evaluated by MarketBeat, and ranked 640th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Emergent Biosolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Emergent Biosolutions has received no research coverage in the past 90 days.

  • Read more about Emergent Biosolutions' stock forecast and price target.
  • Earnings Growth

    Earnings for Emergent Biosolutions are expected to grow in the coming year, from ($0.63) to $2.07 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Emergent Biosolutions is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Emergent Biosolutions is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Emergent Biosolutions has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Emergent Biosolutions' valuation and earnings.
  • Percentage of Shares Shorted

    15.39% of the float of Emergent Biosolutions has been sold short.
  • Short Interest Ratio / Days to Cover

    Emergent Biosolutions has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Emergent Biosolutions has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Emergent Biosolutions does not currently pay a dividend.

  • Dividend Growth

    Emergent Biosolutions does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.39% of the float of Emergent Biosolutions has been sold short.
  • Short Interest Ratio / Days to Cover

    Emergent Biosolutions has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Emergent Biosolutions has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Emergent Biosolutions this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,417.00 in company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Emergent Biosolutions is held by insiders.

  • Percentage Held by Institutions

    78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Emergent Biosolutions' insider trading history.
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

Emergent BioSolutions Inc. (EBS) - Yahoo Finance
Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…
See More Headlines

EBS Stock Analysis - Frequently Asked Questions

Emergent Biosolutions' stock was trading at $9.56 on January 1st, 2025. Since then, EBS stock has decreased by 26.9% and is now trading at $6.99.

Emergent Biosolutions Inc. (NYSE:EBS) posted its earnings results on Wednesday, May, 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.49 by $0.22. The biopharmaceutical company had revenue of $222.20 million for the quarter, compared to analysts' expectations of $218.50 million. Emergent Biosolutions had a negative net margin of 13.63% and a negative trailing twelve-month return on equity of 0.52%.
Read the conference call transcript
.

Emergent Biosolutions' Board of Directors approved a share buyback program on Monday, March 31st 2025, which allows the company to repurchase $50,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 19% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's management believes its shares are undervalued.

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA).

Company Calendar

Last Earnings
5/07/2025
Today
7/03/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NYSE:EBS
Employees
2,420
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.33
High Stock Price Target
$16.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+105.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$190.60 million
Pretax Margin
-6.45%

Debt

Sales & Book Value

Annual Sales
$1.04 billion
Cash Flow
$2.03 per share
Price / Cash Flow
3.44
Book Value
$8.91 per share
Price / Book
0.78

Miscellaneous

Free Float
53,627,000
Market Cap
$379.42 million
Optionable
Optionable
Beta
2.09
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NYSE:EBS) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners